NAD+ Research: Animal Data, Human Trials & What Is Actually Proven
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide. It is grouped with the peptide market because the intact molecule is poorly absorbed by mouth and is instead handled by injection or infusion. The research picture is unusually lopsided: an enormous, strongly positive rodent literature sitting alongside a small and far more cautious set of human trials — most of which studied precursors such as NMN and NR rather than NAD+ itself.
Mechanism of action
NAD+ is the electron carrier at the centre of ATP production. Every mitochondrion depends on it, which is why depletion is linked with systemic fatigue in preclinical models.
PARP enzymes, which detect and repair DNA strand breaks, consume NAD+ directly. Heavy DNA damage draws down the cellular NAD+ pool.
Sirtuins — the enzyme family associated with longevity signalling — are NAD+-dependent. They regulate inflammatory signalling and cellular senescence only while NAD+ availability is adequate.
Tissue NAD+ concentrations decline substantially with age in animal models and in human tissue samples, which is the basis for the entire restoration hypothesis.
The studies
The distinction that matters most on this page is species and route. The dramatic outcomes come from rodents; the human data is smaller, mostly uses oral precursors, and is far more modest. Anything below labelled preclinical has not been shown in people.
Preclinical foundation
NAD+ metabolism and its roles in cellular processes during ageing
What restoring NAD+ actually does in aged animal tissue, across the published body of work.
Nature Reviews Molecular Cell Biology synthesis of animal and cell studies on NAD+ decline, sirtuin and PARP dependence, and restoration strategies
- Declines
- NAD+ with age
- NAD+-dependent
- Sirtuin activity
- Broadly beneficial
- Restoration in rodents
Across multiple tissues and species
- In aged rodents, raising NAD+ improved mitochondrial function, metabolic markers, cognitive performance in disease models and tissue repair capacity.
- The mechanistic case — sirtuins and PARPs both consume NAD+, and the pool falls with age — is well established.
- This is mechanism and animal data. It explains why the hypothesis is taken seriously; it does not demonstrate the same outcomes in humans.
Human clinical evidence
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Whether an oral NAD+ precursor produces a measurable metabolic change in people.
Published in Science · postmenopausal women with prediabetes and overweight or obesity · 250 mg oral NMN daily versus placebo for 10 weeks · hyperinsulinaemic-euglycaemic clamp endpoints
- 10 weeks
- Duration
- Improved
- Muscle insulin sensitivity
- No change
- Body weight / liver fat
- Skeletal-muscle insulin sensitivity and insulin signalling improved significantly versus placebo — the single strongest human result in this field.
- Body weight, body composition, liver fat and blood pressure did not change, which is a long way from the rodent obesity findings.
- The trial used oral NMN, a precursor — not injected or infused NAD+.
Safety and metabolic outcomes of oral NMN supplementation: systematic review and meta-analysis
Whether the precursor trials, pooled together, show consistent real-world benefit.
Published in Nutrients · pooled analysis of randomised controlled trials of oral nicotinamide mononucleotide in adults · safety and metabolism-related endpoints
- Reliably raised
- Blood NAD+ levels
- Generally well tolerated
- Safety profile
- Heterogeneous
- Clinical outcomes
- Oral precursors do what they claim biochemically: they raise circulating NAD+ measurably and safely at studied doses.
- Downstream clinical outcomes are inconsistent across trials — the effect sizes are small and the studies are short.
- Raising a biomarker is not the same as producing a health outcome. This gap is the honest summary of the current human evidence.
Direct NAD+ administration
Intravenous NAD+ versus nicotinamide riboside: retrospective tolerability study
What actually happens when raw NAD+ is infused, compared with infusing a precursor instead.
Published in Frontiers in Aging · retrospective real-world comparison of intravenous NAD+ against intravenous nicotinamide riboside · tolerability and metabolic marker endpoints
- Poor
- IV NAD+ tolerability
- Good
- IV NR tolerability
- Lowered
- HbA1c in the NR group
Required very slow infusion
- Direct IV NAD+ produced notable acute infusion reactions — gastrointestinal cramping, raised heart rate and chest pressure — forcing markedly slower infusion rates.
- The intravenous nicotinamide riboside comparison group was well tolerated and showed a reduction in HbA1c.
- This is the clearest published evidence that the route and the molecule chosen matter more than the marketing suggests. It is retrospective and uncontrolled, so it is signal, not proof.
NAD+ and nicotinamide in addiction and withdrawal models
Whether the long-standing clinic use of IV NAD+ in detoxification has controlled evidence behind it.
Rodent reinstatement model testing nicotinamide on cocaine-seeking behaviour in male and female rats · reviewed alongside historic uncontrolled clinical reports dating to the 1960s
- Signal present
- Animal reinstatement data
- None published
- Controlled human trials
- Uncontrolled
- Clinic reports
- Rodent work shows nicotinamide can influence drug-seeking behaviour, giving the hypothesis a plausible neurochemical basis.
- The widely repeated claim that IV NAD+ eases alcohol and opioid withdrawal rests on historic, uncontrolled clinical observation — not randomised trials.
- Treat this area as unproven in humans. It is the weakest part of the NAD+ evidence base, despite being the most heavily marketed.
Storage & handling
NAD+ research material is supplied as a lyophilised powder and is light-sensitive. Keep sealed vials refrigerated or frozen and protected from light and moisture.
Reconstitute with bacteriostatic water added slowly down the inner wall of the vial; swirl gently until fully dissolved and do not shake. NAD+ solutions are less stable than most peptide solutions.
Store reconstituted solution at 2-8 °C, protect from light, and use within your lab's defined stability window. Avoid repeated freeze-thaw cycles.
Science versus hype: where the evidence actually stands
The same claim can be well supported in mice and entirely unsupported in people. This table separates the two so the gap is visible at a glance.
| Target metric | Preclinical animal data | Human clinical status |
|---|---|---|
| Lifespan and ageing | Extends lifespan and reverses markers of cellular decline in multiple rodent models. | No trial has shown extended human lifespan. No study is designed to. |
| Metabolic function | Reverses diet-induced obesity and insulin resistance in mice. | Oral NMN improved muscle insulin sensitivity in prediabetic women; no weight or liver-fat change. |
| Cognition and clarity | Protects neurons and reduces neuroinflammation in Alzheimer's and injury models. | No controlled trials in healthy adults. Clinic reports are anecdotal. |
| Addiction and withdrawal | Nicotinamide alters drug-seeking behaviour in rodent reinstatement models. | Historic uncontrolled clinical observation only; no randomised evidence. |
All information on this page is provided for laboratory and educational reference only. Peptides Lab SA (PTY) Ltd supplies compounds strictly for in-vitro research use. Nothing here is medical advice, a dosing recommendation, or a claim of human safety or efficacy.